Navigation Links
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Date:7/30/2008

MOUNTAIN VIEW, Calif., July 30 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will release results for its second fiscal quarter ended June 30, 2008, on Wednesday, August 6, 2008, following the close of the U.S. financial markets. The Company will host an investor conference call to discuss the financial results and other clinical development updates at 8:45 a.m. Eastern Time the following day, Thursday, August 7, 2008. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties.

To access the conference call via the Internet, go to http://www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PHY9DE66U.

To access the live conference call via phone, dial 888-680-0894. International callers may access the live call by dialing 617-213-4860. The reference number to enter the call is 37382979.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number to enter the replay of the call is 47372481.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
5. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
6. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
10. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
11. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2008)... CeloNova BioSciences, Inc., annou...h it is commercializing the,CATANIA(TM) Coronary ...t,system that has not had any stent thrombosis in...for purchase throughout Europe and now some Middle...ansion ongoing. Concurrently,CeloNova notes that...
(Date:12/3/2008)... A key element of Carpenter,s EnviroStep&tra...Active Layer RS moisture barrier film is laminated...ls or liquids from soaking in. , ... DuPont today announced it has introduced DuPont&... barrier films for use in carpet cushioning. , , ,...
(Date:12/3/2008)...nis will Outline How Technology Can Solve Pressing... , KINGSTON, ON, Dec. 3 /PRNewswire/ - Dr. D...(PPI), is one of four leading experts speaking at ...Conference underway in Poznan , Poland. Dr. Dennis...s in the 20th Century and the role it will play in...
(Date:12/3/2008)... , CALGARY, Dec. 3 /PRNewswire-FirstCall/ - S...company developing protein pharmaceuticals in crop...hase I/II clinical trial of its plant-produced ins...s. The trial, taking place in the United Kingdom (... three-arm study (SBS-1000 insulin and two commerc...
Breaking Biology Technology:CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3DuPont Launches Innovative Renewably Sourced Material for Carpet Cushion 2DuPont Launches Innovative Renewably Sourced Material for Carpet Cushion 3DuPont Launches Innovative Renewably Sourced Material for Carpet Cushion 4Leading Canadian Scientist to speak at UN Climate Change Conference 2SemBioSys begins phase I/II trial of insulin produced in plant seeds 2SemBioSys begins phase I/II trial of insulin produced in plant seeds 3
..., , , , , , , There is...at can be applied to all PCR amplifications. For e...nce of primer used, the annealing temperatures ,...ing the optimal or the , most stringent ann...results , and efficient amplification of a ...
..., , , , , , , Problems... fragment using the PCR* are an everyday occurrenc...ondary bands may form after the PCR reaction, whic...es (cycle sequencing, mutation detection, , ...ult. In such cases, PCR , conditions must b...
...Optimizing the Direct Amplification of Missing cDN...ler gradient , , , , , , ,...ral Botany, University of Hamburg Christian Rohrer... , , , , , , Introduction...ion forms the basis for detailed , analys...
..., , , , , , , , ...ty of Illinois in Chicago, , USA , ...estbury, NY, USA , , Introduct...a fragment of foreign DNA that has been incorporat...ethod of introducing recombinant DNA , in...
Other Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 2Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 3Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 4Optimizing the Direct Amplification of Missing cDNA 5' Ends, Using the Eppendorf Mastercycler gradient 5The use of TaqMaster PCR Enhancer 2The use of TaqMaster PCR Enhancer 3The use of TaqMaster PCR Enhancer 4The use of TaqMaster PCR Enhancer 5
(Date:12/3/2008)... WASHINGTON Synthetic biology promises to enable ...illion people who suffer from malaria, and to crea...ld,s energy problems. But the science and its app...ologists playing God? Are these scientists purpos...synthetic biology researchers unintentionally equi...
(Date:12/2/2008)... At the Savannah River Site in South Carolina, the...of the surrounding forest. No, they,re not crop c...ng longleaf pine forest ecosystems. Biologists at...aborators at North Carolina State University, the ...ngton have created these ecological patches with t...
(Date:12/2/2008)... This release is available in French . , P...iversity of California, Berkeley, have announced a...led epigenetics. They have demonstrated for the fi... silencing in plants. , The findings are import...lation in the continuing quest to breed enhanced c...
(Date:12/2/2008)... Converting forests or fields to biofuel crops can...pending on where and which biofuel crops are use...month. , The researchers analyzed data from doze...l crops can influence the carbon content of the so...l Global Change Biology Bioenergy . , Plants us...
Breaking Biology News(10 mins):Synthetic biology: Is ethics a showstopper? 2Study on wildlife corridors shows how they work over time 2Study on wildlife corridors shows how they work over time 3Study on wildlife corridors shows how they work over time 4Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3Replacing corn with perennial grasses improves carbon footprint of biofuels 2Replacing corn with perennial grasses improves carbon footprint of biofuels 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 1Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6524 11Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast 6522 1Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast 6522 2FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 1FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 2FDA Updates Label for AVANDIA 28R 29 to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2623 3LUMEDX Introduces Next Generation Cardiology PACS Solution 23879 1LUMEDX Introduces Next Generation Cardiology PACS Solution 23879 2
... Center scientists have demonstrated a new technol...poiling and sometimes dangerous E. coli bacteria. ...spect bacteria as part of the sensing system that ... , The journal Biosensors and Bioelectronics publ... issue. Benjamin Miller, Ph.D., an associate profe...
...mical Senses Center have succeeded in growing matu...he first time have been able to successfully keep ...e establishment of a viable long-term model opens ...s, understanding of the sense of taste and how it ...have an important new tool to help discover molecu...
...inguished by how fast the thinking part of their b...ers at the National Institutes of Health,s (NIH) N...covered. , Magnetic resonance imaging (MRI) scans..., thickens more rapidly during childhood, reaching...cting a longer developmental window for high-level...
...nmental journals from the scientific publisher Spr... to Research in the Environment (OARE), a digital ...rofit institutions in underdeveloped nations in Af...rn Europe will have free access to the peer-review...ding international publishing houses. , Springer,...
Other Biology News:Rochester scientists develop fast-working biosensor 2Living taste cells produced outside the body 2Living taste cells produced outside the body 3Cortex matures faster in youth with highest IQ 2Free access to a digital library for developing countries 2
...ia and other fluid sources for 4 vessels while occ...dual pump is controlled electronically. Both, spee...High-precision controlled peristaltic pumps can be...low rates between 0.01 to 5 L/h with the standard ...
MetaMorph from Universal Imaging Corporation (a subsidiary of Molecular Devices)
Application: Pyronin Y is most widely used in combination with methyl green to selectively and differentially stain nucleic acids following polyacrylamide gel electrophoresis. In a dichromatic dye so
...or the fast and simple integration of loxP-sites i... generation of transgenic mouse models). The inclu...allow neomycin / kanamycin selection in prokaryoti...promoter (gb2) for expression of kanamycin resista...
Biology Products: